Rexinoid bexarotene modulates triglyceride but not cholesterol metabolism via gene-specific permissivity of the RXR/LXR heterodimer in the liver

OBJECTIVE: Bexarotene (Targretin®) is a clinically used anti-tumoral agent which exerts its action through binding to and activation of the Retinoid-X-Receptor (RXR). The most frequent side effect of bexarotene administration is an increase in plasma triglycerides, an independent risk factor of card...

詳細記述

保存先:
書誌詳細
主要な著者: Lalloyer, Fanny, Pedersen, Thomas Åskov, Gross, Barbara, Lestavel, Sophie, Yous, Saïd, Vallez, Emmanuelle, Gustafsson, Jan-Åke, Mandrup, Susanne, Fiévet, Catherine, Staels, Bart, Tailleux, Anne
フォーマット: Artigo
言語:Inglês
出版事項: Lippincott Williams & Wilkins 2009
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC2824837/
https://ncbi.nlm.nih.gov/pubmed/19592467
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/ATVBAHA.109.189506
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料